Nkarta (NKTX) Non Operating Investment Income (2022 - 2026)
Nkarta (NKTX) posted quarterly Non Operating Investment Income of -$537000.0 for Q1 2026, down 2340.91% year-over-year from $23963.5 in Q1 2025, and down 316.28% quarter-over-quarter from -$129000.0 in Q4 2025.
Nkarta (NKTX) Non Operating Investment Income (2022 - 2026) Analysis & Trends
Nkarta's Non Operating Investment Income history runs 5 years deep, the most recent figure standing at -$537000.0 for Q1 2026.
- In Q1 2026, Non Operating Investment Income fell 2340.91% year-over-year to -$537000.0; the TTM figure through Mar 2026 stood at -$782000.0 (down 200.39% YoY), while the FY2025 annual figure was -$267000.0, down 140.09% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$537000.0, down from -$129000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $2.0 million in Q3 2024, with the low at -$1.0 million in Q4 2024.
- The 5-year median for Non Operating Investment Income is -$135000.0 (2024), against an average of $1176.5.
- The sharpest annual moves came in 2024 and 2026: Non Operating Investment Income soared 929.69% in 2024, then plunged 2340.91% in 2026.
- Nkarta's Non Operating Investment Income stood at $642000.0 in 2022, then tumbled by 35.05% to $417000.0 in 2023, then sank by 349.4% to -$1.0 million in 2024, then soared by 87.6% to -$129000.0 in 2025, then plunged by 316.28% to -$537000.0 in 2026.
- Business Quant data shows NKTX's Non Operating Investment Income at -$537000.0 in Q1 2026, -$129000.0 in Q4 2025, and $174000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | -295,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -295,000.00 |
| Jun 30, 2026 | -295,000.00 |
| Mar 31, 2026 | -537,000.00 |
| Mar 31, 2026 | -537,000.00 |
| Dec 31, 2025 | -129,000.00 |
| Dec 31, 2025 | -129,000.00 |
| Sep 30, 2025 | 174,000.00 |
| Sep 30, 2025 | 174,000.00 |
| Jun 30, 2025 | -290,000.00 |
| Jun 30, 2025 | -290,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Dec 31, 2024 | -1.04 Mn |
| Dec 31, 2024 | -1.04 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | -136,000.00 |
| Jun 30, 2024 | -136,000.00 |
| Mar 31, 2024 | -135,000.00 |
| Mar 31, 2024 | -135,000.00 |